U.S. markets closed
  • S&P Futures

    3,790.75
    -12.50 (-0.33%)
     
  • Dow Futures

    30,267.00
    -98.00 (-0.32%)
     
  • Nasdaq Futures

    11,593.00
    -47.75 (-0.41%)
     
  • Russell 2000 Futures

    1,771.40
    -10.10 (-0.57%)
     
  • Crude Oil

    86.57
    +0.05 (+0.06%)
     
  • Gold

    1,732.70
    +2.20 (+0.13%)
     
  • Silver

    21.06
    -0.04 (-0.18%)
     
  • EUR/USD

    0.9983
    -0.0003 (-0.03%)
     
  • 10-Yr Bond

    3.6170
    -0.0340 (-0.93%)
     
  • Vix

    29.07
    -1.03 (-3.42%)
     
  • GBP/USD

    1.1451
    -0.0024 (-0.21%)
     
  • USD/JPY

    143.7840
    -0.4150 (-0.29%)
     
  • BTC-USD

    20,215.12
    +576.04 (+2.93%)
     
  • CMC Crypto 200

    458.92
    +13.48 (+3.03%)
     
  • FTSE 100

    7,086.46
    +177.70 (+2.57%)
     
  • Nikkei 225

    27,173.79
    +181.58 (+0.67%)
     

Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference

·1 min read

PALO ALTO, Calif., August 29, 2022--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York.

Guardant Health’s management is scheduled to participate in a fireside chat on Monday, September 12th at 8:10 a.m. Eastern Time / 5:10 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005115/en/

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michele Rest
press@guardanthealth.com
+1 215-910-2138